Skip to main content
Top
Published in: Advances in Therapy 2/2020

01-05-2020 | Rickets | Review

Complications of Phosphate and Vitamin D Treatment in X-Linked Hypophosphataemia

Author: Pedro Arango Sancho

Published in: Advances in Therapy | Special Issue 2/2020

Login to get access

Abstract

Conventional treatment of X-linked hypophosphataemia (XLH) consists in the oral administration of phosphate plus calcitriol supplements. Although this therapy has reduced bone deformities and even achieved adequate patient growth, overtreatment or low adherence could lead to subsequent consequences that may compromise the efficacy of the therapy. Some of the complications associated with phosphate and vitamin D treatment are abdominal discomfort, diarrhoea, hypokalaemia, hyperparathyroidism, hypercalcaemia or hypercalciuria, nephrocalcinosis or nephrolithiasis, and ectopic calcifications. Therefore, constant multidisciplinary monitoring of patients with XLH is necessary to prevent the manifestation of these complications and to deal with them as soon as they appear. The main objective of this article is to review the main complications arising from conventional treatment of XLH and how to deal with them.
Literature
1.
go back to reference Econs MJ. Conventional therapy in adults with XLH improves dental manifestations, but not enthesopathy. J Clin Endocrinol Metab. 2015;100(10):3622–4.PubMedPubMedCentralCrossRef Econs MJ. Conventional therapy in adults with XLH improves dental manifestations, but not enthesopathy. J Clin Endocrinol Metab. 2015;100(10):3622–4.PubMedPubMedCentralCrossRef
2.
go back to reference Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13–30.PubMedPubMedCentralCrossRef Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13–30.PubMedPubMedCentralCrossRef
3.
go back to reference Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381–8.PubMedCrossRef Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381–8.PubMedCrossRef
4.
go back to reference Carpenter TO. Primary disorders of phosphate metabolism. In: Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, editors. Endotext. South Dartmouth: MDText.com; 2000. Carpenter TO. Primary disorders of phosphate metabolism. In: Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, editors. Endotext. South Dartmouth: MDText.com; 2000.
5.
go back to reference Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003;88(8):3591–7.PubMedCrossRef Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003;88(8):3591–7.PubMedCrossRef
6.
go back to reference Nielsen LH, Rahbek ET, Beck-Nielsen SS, Christesen HT. Treatment of hypophosphataemic rickets in children remains a challenge. Dan Med J. 2014;61(7):A4874.PubMed Nielsen LH, Rahbek ET, Beck-Nielsen SS, Christesen HT. Treatment of hypophosphataemic rickets in children remains a challenge. Dan Med J. 2014;61(7):A4874.PubMed
7.
go back to reference Albright F, Butler AN, Bloomberg E. Rickets resistant to vitamin D therapy. Am J Dis Child. 1937;54(3):529–47. Albright F, Butler AN, Bloomberg E. Rickets resistant to vitamin D therapy. Am J Dis Child. 1937;54(3):529–47.
8.
go back to reference Stickler GB. Familial hypophosphatemic vitamin D resistant rickets. The neonatal period and infancy. Acta Paediatr Scand. 1969;58(3):213–9.PubMedCrossRef Stickler GB. Familial hypophosphatemic vitamin D resistant rickets. The neonatal period and infancy. Acta Paediatr Scand. 1969;58(3):213–9.PubMedCrossRef
9.
go back to reference Paunier L, Kooh SW, Conen PE, Gibson AA, Fraser D. Renal function and histology after long-term vitamin D therapy of vitamin D refractory rickets. J Pediatr. 1968;73(6):833–44.PubMedCrossRef Paunier L, Kooh SW, Conen PE, Gibson AA, Fraser D. Renal function and histology after long-term vitamin D therapy of vitamin D refractory rickets. J Pediatr. 1968;73(6):833–44.PubMedCrossRef
10.
go back to reference Lilly CA, Peirce CB, Grant RL. The effect of phosphates on the bones of rachitic rats: three plates (twelve figures). J Nutr. 1935;9(1):25–35.CrossRef Lilly CA, Peirce CB, Grant RL. The effect of phosphates on the bones of rachitic rats: three plates (twelve figures). J Nutr. 1935;9(1):25–35.CrossRef
11.
go back to reference Fraser D, Geiger DW, Munn JD, Slater PE, Jahn R, Liu E. Clinical vitamin-D deficiency and in hypophosphatemic vitamin-D-refractory rickets-the induction of calcium deposition in rachitic cartilage without the administration of vitamin-D. Am J Dis Child. 1958;96(4):460–3. Fraser D, Geiger DW, Munn JD, Slater PE, Jahn R, Liu E. Clinical vitamin-D deficiency and in hypophosphatemic vitamin-D-refractory rickets-the induction of calcium deposition in rachitic cartilage without the administration of vitamin-D. Am J Dis Child. 1958;96(4):460–3.
12.
go back to reference Marie PJ, Travers R, Glorieux FH. Healing of bone lesions with 1,25-dihydroxyvitamin D3 in the young X-linked hypophosphatemic male mouse. Endocrinology. 1982;111(3):904–11.PubMedCrossRef Marie PJ, Travers R, Glorieux FH. Healing of bone lesions with 1,25-dihydroxyvitamin D3 in the young X-linked hypophosphatemic male mouse. Endocrinology. 1982;111(3):904–11.PubMedCrossRef
13.
go back to reference Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest. 1985;75(6):1858–68.PubMedPubMedCentralCrossRef Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest. 1985;75(6):1858–68.PubMedPubMedCentralCrossRef
14.
go back to reference Block JE, Piel CF, Selvidge R, Genant HK. Familial hypophosphatemic rickets: bone mass measurements in children following therapy with calcitriol and supplemental phosphate. Calcif Tissue Int. 1989;44(2):86–92.PubMedCrossRef Block JE, Piel CF, Selvidge R, Genant HK. Familial hypophosphatemic rickets: bone mass measurements in children following therapy with calcitriol and supplemental phosphate. Calcif Tissue Int. 1989;44(2):86–92.PubMedCrossRef
15.
go back to reference Haris A, Toth A, Rado JP. High-dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia. Exp Clin Endocrinol Diabetes. 1998;106(5):431–4.PubMedCrossRef Haris A, Toth A, Rado JP. High-dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia. Exp Clin Endocrinol Diabetes. 1998;106(5):431–4.PubMedCrossRef
16.
go back to reference Zivicnjak M, Schnabel D, Billing H, et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol. 2011;26(2):223–31.PubMedCrossRef Zivicnjak M, Schnabel D, Billing H, et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol. 2011;26(2):223–31.PubMedCrossRef
17.
go back to reference Kooh SW, Binet A, Daneman A. Nephrocalcinosis in X-linked hypophosphataemic rickets: its relationship to treatment, kidney function, and growth. Clin Invest Med. 1994;17(2):123–30.PubMed Kooh SW, Binet A, Daneman A. Nephrocalcinosis in X-linked hypophosphataemic rickets: its relationship to treatment, kidney function, and growth. Clin Invest Med. 1994;17(2):123–30.PubMed
18.
go back to reference Sellarés VL, Martín de Francisco AL, Torregrosa V. Alteraciones del metabolismo mineral en la enfermedad renal crónica. Nefrologia. 2012;7(1):483–503. Sellarés VL, Martín de Francisco AL, Torregrosa V. Alteraciones del metabolismo mineral en la enfermedad renal crónica. Nefrologia. 2012;7(1):483–503.
19.
go back to reference Davies M. Hyperparathyroidism in X-linked hypophosphataemic osteomalacia. Clin Endocrinol (Oxf). 1995;42(2):205–6.CrossRef Davies M. Hyperparathyroidism in X-linked hypophosphataemic osteomalacia. Clin Endocrinol (Oxf). 1995;42(2):205–6.CrossRef
20.
go back to reference Arnaud C, Glorieux F, Scriver C. Serum parathyroid hormone in X-linked hypophosphatemia. Science. 1971;173(3999):845–7.PubMedCrossRef Arnaud C, Glorieux F, Scriver C. Serum parathyroid hormone in X-linked hypophosphatemia. Science. 1971;173(3999):845–7.PubMedCrossRef
21.
go back to reference Kruse K, Hinkel GK, Griefahn B. Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets. Eur J Pediatr. 1998;157(11):894–900.PubMedCrossRef Kruse K, Hinkel GK, Griefahn B. Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets. Eur J Pediatr. 1998;157(11):894–900.PubMedCrossRef
22.
go back to reference Goodyer PR, Kronick JB, Jequier S, Reade TM, Scriver CR. Nephrocalcinosis and its relationship to treatment of hereditary rickets. J Pediatr. 1987;111(5):700–4.PubMedCrossRef Goodyer PR, Kronick JB, Jequier S, Reade TM, Scriver CR. Nephrocalcinosis and its relationship to treatment of hereditary rickets. J Pediatr. 1987;111(5):700–4.PubMedCrossRef
23.
24.
go back to reference Glorieux FH, Marie PJ, Pettifor JM, Delvin EE. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med. 1980;303(18):1023–31.PubMedCrossRef Glorieux FH, Marie PJ, Pettifor JM, Delvin EE. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med. 1980;303(18):1023–31.PubMedCrossRef
25.
go back to reference Makitie O, Kooh SW, Sochett E. Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol (Oxf). 2003;58(2):163–8.CrossRef Makitie O, Kooh SW, Sochett E. Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol (Oxf). 2003;58(2):163–8.CrossRef
26.
27.
go back to reference Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008;3(3):658–64.PubMedPubMedCentralCrossRef Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008;3(3):658–64.PubMedPubMedCentralCrossRef
28.
go back to reference Chocron S, Lara LE, Madrid A, Muñoz M, Vilalta R, Ariceta G. Cinacalcet allows reduction of oral phosphate dose and PTH control in XLHR. Preliminary data. Pediatr Nephrol. 2014;29:1684 (Abstract O78). Chocron S, Lara LE, Madrid A, Muñoz M, Vilalta R, Ariceta G. Cinacalcet allows reduction of oral phosphate dose and PTH control in XLHR. Preliminary data. Pediatr Nephrol. 2014;29:1684 (Abstract O78).
29.
go back to reference Dong BJ. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005;27(11):1725–51.PubMedCrossRef Dong BJ. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005;27(11):1725–51.PubMedCrossRef
30.
go back to reference de Francisco AL. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opin Pharmacother. 2008;9(5):795–811.PubMedCrossRef de Francisco AL. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opin Pharmacother. 2008;9(5):795–811.PubMedCrossRef
31.
go back to reference Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin O. Hypertension in hypophosphatemic rickets—role of secondary hyperparathyroidism. Pediatr Nephrol. 2003;18(2):155–8.PubMedCrossRef Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin O. Hypertension in hypophosphatemic rickets—role of secondary hyperparathyroidism. Pediatr Nephrol. 2003;18(2):155–8.PubMedCrossRef
32.
go back to reference Colares Neto G, Yamamuchi FI, Baroni RH, et al. Nephrocalcinosis and nephrolithiasis in 36 X-linked hypophosphatemic rickets patients: diagnostic imaging and evaluation of risk factors in a single-center study (Poster 218-P2). In: 51st Annual Meeting European Society of Paediatric Endocrinology (ESPE); 2015 October 1–3; Barcelona, Spain. Colares Neto G, Yamamuchi FI, Baroni RH, et al. Nephrocalcinosis and nephrolithiasis in 36 X-linked hypophosphatemic rickets patients: diagnostic imaging and evaluation of risk factors in a single-center study (Poster 218-P2). In: 51st Annual Meeting European Society of Paediatric Endocrinology (ESPE); 2015 October 1–3; Barcelona, Spain.
33.
go back to reference Alon U, Brewer WH, Chan JC. Nephrocalcinosis: detection by ultrasonography. Pediatrics. 1983;71(6):970–3.PubMed Alon U, Brewer WH, Chan JC. Nephrocalcinosis: detection by ultrasonography. Pediatrics. 1983;71(6):970–3.PubMed
34.
go back to reference Keskin M, Savas-Erdeve S, Sagsak E, Cetinkaya S, Aycan Z. Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets. J Pediatr Endocrinol Metab. 2015;28(11–12):1333–7.PubMed Keskin M, Savas-Erdeve S, Sagsak E, Cetinkaya S, Aycan Z. Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets. J Pediatr Endocrinol Metab. 2015;28(11–12):1333–7.PubMed
35.
go back to reference Karaplis AC, Bai X, Falet JP, Macica CM. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice. Endocrinology. 2012;153(12):5906–17.PubMedPubMedCentralCrossRef Karaplis AC, Bai X, Falet JP, Macica CM. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice. Endocrinology. 2012;153(12):5906–17.PubMedPubMedCentralCrossRef
36.
go back to reference Polisson RP, Martínez S, Khoury M, et al. Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med. 1985;313(1):1–6.PubMedCrossRef Polisson RP, Martínez S, Khoury M, et al. Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med. 1985;313(1):1–6.PubMedCrossRef
37.
go back to reference Moltz KC, Friedman AH, Nehgme RA, Kleinman CS, Carpenter TO. Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets. Curr Opin Pediatr. 2001;13(4):373–5.PubMedCrossRef Moltz KC, Friedman AH, Nehgme RA, Kleinman CS, Carpenter TO. Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets. Curr Opin Pediatr. 2001;13(4):373–5.PubMedCrossRef
38.
go back to reference Seikaly MG, Brown R, Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics. 1997;100(5):879–84.PubMedCrossRef Seikaly MG, Brown R, Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics. 1997;100(5):879–84.PubMedCrossRef
39.
go back to reference Makitie O, Toiviainen-Salo S, Marttinen E, Kaitila I, Sochett E, Sipila I. Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets. Horm Res. 2008;69(4):212–20.PubMed Makitie O, Toiviainen-Salo S, Marttinen E, Kaitila I, Sochett E, Sipila I. Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets. Horm Res. 2008;69(4):212–20.PubMed
40.
go back to reference Schütt SM, Schumacher M, Holterhus PM, Felgenhauer S, Hiort O. Effect of GH replacement therapy in two male siblings with combined X-linked hypophosphatemia and partial GH deficiency. Eur J Endocrinol. 2003;149(4):317–21.PubMedCrossRef Schütt SM, Schumacher M, Holterhus PM, Felgenhauer S, Hiort O. Effect of GH replacement therapy in two male siblings with combined X-linked hypophosphatemia and partial GH deficiency. Eur J Endocrinol. 2003;149(4):317–21.PubMedCrossRef
41.
go back to reference Mirza MA, Alsio J, Hammarstedt A, et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2011;31(1):219–27.PubMedCrossRef Mirza MA, Alsio J, Hammarstedt A, et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2011;31(1):219–27.PubMedCrossRef
43.
go back to reference Carpenter TO, Insogna KL, Zhang JH, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab. 2010;95(11):E352–7.PubMedPubMedCentralCrossRef Carpenter TO, Insogna KL, Zhang JH, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab. 2010;95(11):E352–7.PubMedPubMedCentralCrossRef
44.
go back to reference Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23(9):1509–18.PubMedCrossRef Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23(9):1509–18.PubMedCrossRef
45.
go back to reference Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24(11):1879–88.PubMedCrossRef Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24(11):1879–88.PubMedCrossRef
46.
go back to reference Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587–97.PubMedPubMedCentralCrossRef Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587–97.PubMedPubMedCentralCrossRef
47.
go back to reference Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987–98.PubMedCrossRef Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987–98.PubMedCrossRef
Metadata
Title
Complications of Phosphate and Vitamin D Treatment in X-Linked Hypophosphataemia
Author
Pedro Arango Sancho
Publication date
01-05-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue Special Issue 2/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-01170-7

Other articles of this Special Issue 2/2020

Advances in Therapy 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine